Methods	2 week randomised study
Participants	Diagnosis: DSM-IV major depressive disorder, single episode Setting: Psychiatric inpatients
Interventions	1. Mirtazapine: mean 38.2 (SD 9.0) mg/day, N = 20 2. Reboxetine: mean 6.6 (SD 1.9) mg/day, N = 20 Flexible dosing scheduling
Outcomes	The measure used for primary outcome: Performance in driving simulator Other measures: HAM-D, BDI
Notes	Only information about attrition of the participants is available for the present review
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: “randomised” Comment: No further information provided.
Allocation concealment (selection bias)	Unclear risk	Comment: The method of concealment is not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Comment: No further information provided.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Less than 20% of the participants dropped out and missing outcome data are balanced in numbers across intervention groups, with similar reasons of missing data across groups
Selective reporting (reporting bias)	Unclear risk	No useful information in terms of depression severity at the end of treatment is provide
Free of Sponsorship bias?	High risk	The funding source is the pharmaceutical company of the comparator drug